Eisai Co., Ltd. (ESALF)
| Market Cap | 10.85B |
| Revenue (ttm) | 4.56B |
| Net Income (ttm) | 202.95M |
| Shares Out | n/a |
| EPS (ttm) | 0.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Open | 36.00 |
| Previous Close | 38.50 |
| Day's Range | 35.98 - 36.00 |
| 52-Week Range | 30.23 - 57.50 |
| Beta | -0.08 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2024 |
About Eisai
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a... [Read more]
Full Company ProfileFinancial Performance
In 2023, Eisai's revenue was 741.75 billion, a decrease of -0.36% compared to the previous year's 744.40 billion. Earnings were 42.41 billion, a decrease of -23.50%.
Financial numbers in JPY Financial StatementsNews
Merck Keytruda with Eisai’s Lenvima succeeds in late-stage trial for liver cancer
Merck's (MRK) Keytruda in combination with Eisai's (ESALY) Lenvima hit main goal ina late-stage trial for liver cancer. Read more here.
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
In the Phase 3 LEAP-012 trial, KEYTRUDA plus LENVIMA in combination with TACE reduced the risk of disease progression or death by 34% compared to TACE alone Late-breaking first interim analysis result...
Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges
Biogen Inc. (NASDAQ: BIIB) and Eisai Ltd’s (OTC: ESALY) Alzheimer’s drug Leqembi (lecanemab) is reportedly offering hope for patients in the early stages of the disease despite it not being a cure. ...
Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others. But patients face a long road to tre...
Biogen, Eisai new Alzheimer’s drug considered too costly in Britain
Biogen (BIIB) and Eisai's (ESALF) face setback in U.K. for Alzheimer's drug Leqembi as a public body in the country didn't recommend it for coverage. Read more here.
Biogen/Eisai’s Alzheimer's drug wins marketing authorization in Great Britain
UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug
Alzheimer's patients in Britain's state-run health service is unlikely to get access to Eisai and Biogen's new Leqembi drug, after it was approved by the country's regulator but deemed too expensive f...
Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED
Eisai Co Ltd (ESALF) Q1 2025 Earnings Call Transcript
Eisai Co Ltd (OTCPK:ESALF) Q1 2025 Results Conference Call August 2, 2024 2:00 AM ET Company Participants Mitsuru Shomon - Chief Financial Officer Keisuke Naito - Representative Corporate Officer and ...
Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest
The benefit of Eisai and Biogen's Alzheimer's drug Leqembi in patients with early-stage Alzheimer's appears to increase with continued use with no new safety issues, according to three-year data prese...
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
The breakthrough Alzheimer's drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term. That's according to new data pres...
Shares of Japan's Eisai tumble after EU rejects Alzheimer's drug
Shares of Japan's Eisai tumbled 11% and were on track for their biggest one-day fall in three years on Monday, after the European Union's regulator rejected the drugmaker's Leqembi treatment for early...
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
European drug regulators rejected the Alzheimer's treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. The Eu...
EU medicines regulator rejects Eisai-Biogen Alzheimer's drug
The European Union's drugs regulator on Friday rejected Eisai and Biogen's breakthrough treatment for early Alzheimer's disease, in a blow to the drugmakers as take-up in the U.S. has been slower than...
Eisai Selects Medidata's Clinical Data Studio to Enhance and Modernize Clinical Trial Efficiency and Patient Experience
NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced Eisai Inc. (“Eisai”), the U.S. pharmaceut...
EISAI TO BEGIN ENROLLING STUDY IN PATIENTS WITH NARCOLEPSY
NUTLEY, N.J. , July 8, 2024 /PRNewswire/ -- Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective o...
Eisai: Margin Of Safety From Very Modest Penetration Expectations
Eisai's story revolves around Leqembi and Lenvima, with Leqembi launching in Japan and expected to reach 10% of necessary revenue for fair value by end of year. Leqembi sales projected to hit 50 billi...
Japan's Eisai developing dementia drug for US market, Nikkei reports
Japanese drugmaker Eisai is developing a dementia treatment that it aims to commercialise in the U.S. by fiscal 2030, the Nikkei reported on Sunday.
Alzheimer's Disease Drug Development: Another Lost Year
Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of...
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study
Eisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the end of March.
RBC lists antibody-drug conjugates (ADCs) as $30 billion category by 2030
CNBC's Angelica Peebles reports on opportunities in the pharmaceutical sector.
Advanced Infusion Care (AIC) now offers Eisai infusion therapy LEQEMBI™ (Lecanemab-irmb) humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody
DALLAS--(BUSINESS WIRE)--Advanced Infusion Care, a division of AIS Healthcare, now offers LEQEMBI™, developed by Eisai Co., Ltd., for the treatment of patients with Alzheimer's disease. The nationally...
Eisai: Potentially The Best Bet On The Alzheimer's Treatment Market
Leading pharmaceutical companies are making progress in developing and commercializing treatments for Alzheimer's Disease, one of the most prevalent conditions among the elderly population. Eisai is m...
Merck and Eisai report disappointing results from trials of combination treatment for melanoma and colorectal cancer
Merck MRK and its Japanese partner Eisai said Friday they are discontinuing the Phase 3 LEAP-003 trial evaluating Keytruda plus Lenvima for the first-line treatment of adults with unresectable or meta...
Alzheimer's patients retain the benefits of Leqembi even when they stop the drug, Eisai says
Alzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows.